Clinical trialsCompany release

Veradermics reports positive VDPHL01 hair loss data and $798.4M cash runway into 2030

🇺🇸 Veradermics, Inc (MANE) · Tue 10 Nov 2026

The US company says two male pattern hair loss studies of its extended-release oral minoxidil were positive, with no treatment-related serious or cardiac adverse events of special interest.

Veradermics, Inc reported its third-quarter 2026 results on 10 November and gave an update on VDPHL01, an extended-release oral minoxidil tablet it is developing for pattern hair loss.

According to the company, Phase 3 Study 304 and the 12-month Phase 2/3 Study 302, both in men, were positive. Veradermics said there were no treatment-related serious adverse events and no cardiac adverse events of special interest in the studies.

Topline data from Study 306, which is in female patients, are expected in the first half of 2027.

On the financial side, Veradermics reported cash and securities of $798.4 million and a net loss of $21.0 million for the quarter. The headline of the company's announcement says this funds operations into 2030. The summary available does not include efficacy figures, dosing details or any regulatory submission timelines.

What it means for your team

  • Safety is the point to watch: the company reports no treatment-related serious adverse events and no cardiac adverse events of special interest, a key area for any oral minoxidil product.
  • Female-patient data from Study 306 are due in the first half of 2027 and will shape the breadth of any eventual label.
  • No efficacy figures or filing plans were available in the material reviewed, so regulatory and market-access teams should wait for fuller data before assessing positioning.
  • The stated cash position of $798.4 million, said to fund operations into 2030, suggests the programme is not near-term financing-constrained.

Company's press release (SEC filing): Veradermics, Inc ↗

Article written by VigiEye from the official source (Veradermics, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →